0000000000810869

AUTHOR

Maria Giovanna Lupo

0000-0002-4236-4414

showing 1 related works from this author

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile

2021

Abstract Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemiaPCSK9chemistry.chemical_compoundInternal medicineLomitapide Lipoprotein (a) PCSK9 Familial HypercholesterolemiaLipoprotein (a)Internal MedicinemedicineDiseases of the circulatory (Cardiovascular) systemFamilial Hypercholesterolemiaskin and connective tissue diseasesmedia_commonLdl cholesterolmedicine.diagnostic_testbusiness.industryPCSK9nutritional and metabolic diseasesPlasma levelsmedicine.diseaseLomitapideLomitapidelp(a)EndocrinologychemistryRC666-701pcsk9.lipids (amino acids peptides and proteins)sense organsCardiology and Cardiovascular MedicineLipid profilebusiness
researchProduct